• Publications
  • Influence
Update of EULAR recommendations for the treatment of systemic sclerosis
The aim was to update the 2009 European League against Rheumatism recommendations for the treatment of systemic sclerosis, with attention to new therapeutic questions, which resulted in 16 recommendations being developed that address treatment of several SSc-related organ complications. Expand
The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement
In this nationwide register, a descriptive classification of patients with disease manifestations characteristic of SSc in five groups allows to include a broader spectrum of Patients with features of S sc to improve the detection and follow-up of patients presenting with different disease manifestations. Expand
Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features
This study shows that five autoantigens (that is, centromere, topoisomerase I, PM-Scl, U1-RNP and RNAP) detected more than 95% of the known SSc-associated antibody responses in ANA-positive SSc patients and characterise around 79% of all S sc patients in a central European cohort. Expand
The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response
The members of the Paediatric Rheumatology International Trials Organisation propose a core set of criteria for the evaluation of response to therapy that is scientifically and clinically relevant and statistically validated and will help standardize the conduct and reporting of clinical trials and assist practitioners in deciding whether a child with juvenile DM has responded adequately to therapy. Expand
The German etanercept registry for treatment of juvenile idiopathic arthritis.
Etanercept treatment was safe and led to a significant improvement in most JIA patients resistant to conventional treatment, and lower in patients with systemic onset arthritis. Expand
Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA
The patients' disease activity improved during etanercept monotherapy and etanorcept and methotrexate combination therapy and Tolerability in both treatment groups was comparable. Expand
Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis
An interdisciplinary, evidence-based treatment guideline for JIA uveitis is presented and an algorithm for anti-inflammatory treatment and final statements confirmed in a Delphi method are presented. Expand
Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database.
Juvenile SSc appears to be less severe than in adults because children have less internal organ involvement, a less specific autoantibody profile, and a better long-term outcome. Expand
European dermatology forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis
The term ‘sclerosing diseases of the skin’ comprises specific dermatological entities which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypesExpand
Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study.
The insidious onset of the disease, the delay in diagnosis, the recognition of mixed subtype and the better definition of the other subtypes should influence the efforts in educating trainees and practitioners and help in developing a comprehensive classification system for this syndrome. Expand